Camilla Labrie

Leiden University Medical Center — Netherlands

Biochemistry, Genetics and Molecular Biology · Life Sciences

7h-index267citations63works3.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(43), Viral gastroenteritis research and epidemiology(38), Cancer Research and Treatments(36), Cancer Immunotherapy and Biomarkers(10), Immunodeficiency and Autoimmune Disorders(10)

Publications63 total

794 CD163+ macrophages are an effective target for antitumor therapy
Regular and Young Investigator Award Abstracts·2025Open Access
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy
Cancer Cell·2024· 118 citedOpen Access
Figure S2 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies
2024Open Access
Figure S6 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies
2024Open Access
Figure S6 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies
2024Open Access
Supplementary Tables S1-S3 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies
2024Open Access
Figure S10 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies
2024Open Access
Figure S11 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies
2024Open Access
Figure S1 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies
2024Open Access
Figure S8 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies
2024Open Access
Figure S7 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies
2024Open Access
Figure S14 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies
2024Open Access
Figure S9 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies
2024Open Access
Figure S13 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies
2024Open Access
Figure S8 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies
2024Open Access
Figure S15 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies
2024Open Access
Figure S3 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies
2024Open Access
Figure S4 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies
2024Open Access
Figure S7 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies
2024Open Access
Figure S2 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies
2024Open Access
page 1 of 4Next →

Frequent Co-authors

Sjoerd H. van der Burg(50), Thorbald van Hall(49), Christianne Groeneveldt(44), Priscilla Kinderman(44), Lisa Griffioen(44), Diana J.M. van den Wollenberg(44), Rob C. Hoeben(44), Nadine van Montfoort(44), Olivia Rensing(26), Matt Coffey(26), Houra Loghmani(26), Els M.E. Verdegaal(26), Marij J.P. Welters(26), Marjolein Sluijter(19), Jurriaan Q. van Ginkel(17), Peter ten Dijke(17), Lukas J.A.C. Hawinkels(17), Marit J van Elsas(4), Elham Beyranvand Nejad(3), Ramon Arens(3)